Harriet Mayanja-Kizza
Born
Uganda
NationalityUgandan
CitizenshipUganda
Alma materMakerere University
(Bachelor of Medicine and Bachelor of Surgery)
(Master of Medicine in Medicine)
Case Western Reserve University
(Master of Science in Immunology)
American College of Physicians
(Fellow of the American College of Physicians)
Occupation(s)Medical researcher, academic administrator
Years active1978–present
TitleFormer Dean
Makerere University School of Medicine

Harriet Mayanja-Kizza, MBChB, MMed, MSc, FACP, is a Ugandan physician, researcher, and academic administrator. She is the former Dean of Makerere University School of Medicine,[1][2] the oldest medical school in East Africa,[3] established in 1924.[4]

Background and education

She was born in the Central Region of Uganda in the 1950s. She holds the degree of Bachelor of Medicine and Bachelor of Surgery, obtained from Makerere University in 1978. She also holds the degree of Master of Medicine in Internal Medicine, obtained in 1983, also from Makerere. She studied immunology and pathology at Case Western Reserve University in Cleveland, Ohio, USA, graduating with the degree of Master of Science in those fields in 1999.[2] She is a Fellow of the American College of Physicians.[5]

Career

Mayanja-Kizza has worked as a lecturer in the Department of Internal Medicine at Makerere University Medical School. She has also served as the head of the Department of Internal Medicine, both at the medical school and at Mulago National Referral Hospital, the university's teaching hospital. In November 2010, she was appointed dean of the Makerere Medical School, at Makerere University College of Health Sciences.[5][6] She has presented widely at national, regional, and International conferences and has published extensively in peer journals.[7] In 2022, she was ranked by the AD Scientific Index as the best scientist in Uganda.[8][9][10]

Other considerations

Her area of specialization is immunology, focusing on the interaction between AIDS and tuberculosis. Her research studies, are in the areas of immunopathogenesis, and immune-modulation treatments among patients with human immunodeficiency virus infection and tuberculosis.[2] Professor Harriet Mayanja-Kizza is a Fellow of the Uganda National Academy of Sciences.[11]

See also

Research

She is a respected researcher with more than 200 publications and 9277 citations of her works as of May 2022.[12] Some of her articles with more than 100 citations include; A blood RNA signature for tuberculosis disease risk: a prospective cohort study (2016),[13] Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy (2008),[14] A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis (2004),[15] Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients (2001),[16] Patient and health service delay in pulmonary tuberculosis patients attending a referral hospital: a cross-sectional study (2005),[17] Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy (2007),[18] Four-gene pan-African blood signature predicts progression to tuberculosis (2018),[19] Sero-prevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda (2010),[20] Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities (2015),[21] Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda (2005),[22] Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS (1998),[23] Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population (2009),[24] Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection (2018),[25] IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure (2019),[26] Genome scan of M. tuberculosis infection and disease in Ugandans (2008),[27] Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a national referral hospital in Kampala, Uganda (2007),[28] Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB (2016),[29] The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study (2012),[30] High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort (2011),[31] FCRL5 Delineates Functionally Impaired Memory B Cells Associated with Plasmodium falciparum Exposure (2015),[32] Concise gene signature for point‐of‐care classification of tuberculosis (2016), Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection (2010)[33]

References

  1. ↑ "Accordia's Academic Alliance: Harriet Mayanja-Kizza, MBChB, MMed, MSc". Accordia Foundation. Archived from the original on 26 December 2014. Retrieved 26 December 2014.
  2. 1 2 3 "Profile of Professor Harriet Mayanja-Kizza; Dean, School of Medicine at Makerere University College of Health Sciences". Kampala: Uganda Campus Times. 3 December 2014. Retrieved 4 November 2016.
  3. ↑ "Uganda Virus Research Institute: Our Partners". Entebbe: Uganda Virus Research Institute. 11 April 2014. Retrieved 27 December 2014.
  4. ↑ "Makerere University Medical School Was Founded In 1924". Columbia University Medical College (CUMC). 26 December 2014. Archived from the original on 9 December 2014. Retrieved 26 December 2014.
  5. 1 2 "2011 Sub-Saharan Africa CFAR Conference: Speaker Bio - Harriet Mayanja-Kizza, MBChB, MMed, MSc, FACP". University of California San Francisco. 27 May 2011. Archived from the original on 5 June 2015. Retrieved 26 December 2014.
  6. ↑ "Academic Profile of Professor Harriet Mayanja-Kizza". Infectious Diseases Institute. Retrieved 26 December 2014.
  7. ↑ "In Depth Review Professor Harriet Mayanja-Kizza's Work". 2009 The Clinical Infectious Diseases Research Initiative. 2009. Archived from the original on 26 December 2014. Retrieved 26 December 2014.
  8. ↑ Reporter, C. B. (2022-05-17). "Makerere Has the Best Scientists in the Country - Report". Campus Bee. Retrieved 2022-07-09.
  9. ↑ "Harriet Mayanja-Kizza - AD Scientific Index 2022". www.adscientificindex.com. Retrieved 2022-07-09.
  10. ↑ admin (2022-05-19). "Who are Uganda's Top 500 Scientists of 2022? A new report finds out". MediaScape News. Retrieved 2022-07-09.
  11. ↑ "UNAS: Fellow Profile". Uganda National Academy of Science. Archived from the original on 2 March 2015. Retrieved 26 December 2014.
  12. ↑ "Harriet Mayanja-Kizza". scholar.google.com. Retrieved 2022-05-22.
  13. ↑ Zak, Daniel E; Penn-Nicholson, Adam; Scriba, Thomas J; Thompson, Ethan; Suliman, Sara; Amon, Lynn M; Mahomed, Hassan; Erasmus, Mzwandile; Whatney, Wendy; Hussey, Gregory D; Abrahams, Deborah (2016-06-04). "A blood RNA signature for tuberculosis disease risk: a prospective cohort study". The Lancet. 387 (10035): 2312–2322. doi:10.1016/S0140-6736(15)01316-1. ISSN 0140-6736. PMC 5392204. PMID 27017310. S2CID 53393545.
  14. ↑ Kambugu, Andrew; Meya, David B.; Rhein, Joshua; O'Brien, Meagan; Janoff, Edward N.; Ronald, Allan R.; Kamya, Moses R.; Mayanja-Kizza, Harriet; Sande, Merle A.; Bohjanen, Paul R.; Boulware, David R. (2008-06-01). "Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy". Clinical Infectious Diseases. 46 (11): 1694–1701. doi:10.1086/587667. ISSN 1058-4838. PMC 2593910. PMID 18433339.
  15. ↑ Wallis, Robert S.; Kyambadde, Peter; Johnson, John L.; Horter, Libby; Kittle, Rodney; Pohle, Monika; Ducar, Constance; Millard, Monica; Mayanja-Kizza, Harriet; Whalen, Christopher; Okwera, Alphonse (2004-01-23). "A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis". AIDS. 18 (2): 257–264. doi:10.1097/00002030-200401230-00015. ISSN 0269-9370. PMID 15075543. S2CID 17623568.
  16. ↑ Toossi, Z; Mayanja-Kizza, H; Hirsch, C S; Edmonds, K L; Spahlinger, T; Hom, D L; Aung, H; Mugyenyi, P; Ellner, J J; Whalen, C W (2001-02-01). "Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients". Clinical and Experimental Immunology. 123 (2): 233–238. doi:10.1046/j.1365-2249.2001.01401.x. ISSN 0009-9104. PMC 1905977. PMID 11207653.
  17. ↑ Kiwuwa, Mpungu S.; Charles, Karamagi; Harriet, Mayanja Kizza (2005-11-24). "Patient and health service delay in pulmonary tuberculosis patients attending a referral hospital: a cross-sectional study". BMC Public Health. 5 (1): 122. doi:10.1186/1471-2458-5-122. ISSN 1471-2458. PMC 1310609. PMID 16307685.
  18. ↑ Kamya, Moses R.; Mayanja-Kizza, Harriet; Kambugu, Andrew; Bakeera-Kitaka, Sabrina; Semitala, Fred; Mwebaze-Songa, Patricia; Castelnuovo, Barbara; Schaefer, Petra; Spacek, Lisa A.; Gasasira, Anne F.; Katabira, Elly (2007-10-01). "Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy". Journal of Acquired Immune Deficiency Syndromes. 46 (2): 187–193. doi:10.1097/QAI.0b013e31814278c0. ISSN 1525-4135. PMID 17693883. S2CID 41634539.
  19. ↑ Suliman, Sara; Thompson, Ethan G.; Sutherland, Jayne; Weiner, January; Ota, Martin O. C.; Shankar, Smitha; Penn-Nicholson, Adam; Thiel, Bonnie; Erasmus, Mzwandile; Maertzdorf, Jeroen; Duffy, Fergal J. (2018-05-01). "Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis". American Journal of Respiratory and Critical Care Medicine. 197 (9): 1198–1208. doi:10.1164/rccm.201711-2340OC. ISSN 1073-449X. PMC 6019933. PMID 29624071.
  20. ↑ Ziraba, Abdhalah K.; Bwogi, Josephine; Namale, Alice; Wainaina, Caroline W.; Mayanja-Kizza, Harriet (2010-06-29). "Sero-prevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda". BMC Infectious Diseases. 10 (1): 191. doi:10.1186/1471-2334-10-191. ISSN 1471-2334. PMC 2910699. PMID 20587047.
  21. ↑ Helb, Danica A.; Tetteh, Kevin K. A.; Felgner, Philip L.; Skinner, Jeff; Hubbard, Alan; Arinaitwe, Emmanuel; Mayanja-Kizza, Harriet; Ssewanyana, Isaac; Kamya, Moses R.; Beeson, James G.; Tappero, Jordan (2015-08-11). "Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities". Proceedings of the National Academy of Sciences of the United States of America. 112 (32): E4438–4447. Bibcode:2015PNAS..112E4438H. doi:10.1073/pnas.1501705112. ISSN 1091-6490. PMC 4538641. PMID 26216993.
  22. ↑ Mayanja-Kizza, Harriet; Jones-Lopez, Edward; Okwera, Alphonse; Wallis, Robert S.; Ellner, Jerrold J.; Mugerwa, Roy D.; Uganda–Case Western Research Collaboration (2005-03-15). "Immunoadjuvant Prednisolone Therapy for HIV-Associated Tuberculosis: A Phase 2 Clinical Trial in Uganda". The Journal of Infectious Diseases. 191 (6): 856–865. doi:10.1086/427995. ISSN 0022-1899. PMC 4515766. PMID 15717259.
  23. ↑ Kizza, Harriet Mayanja; Oishi, Kazunori; Mitarai, Satoshi; Yamashita, Hiroshi; Nalongo, Kisembo; Watanabe, Kiwao; Izumi, Takashi; Jungala, Ococi; Augustine, Kaddhu; Mugerwa, Roy; Nagatake, Tsuyoshi (1998-06-01). "Combination Therapy with Fluconazole and Flucytosine for Cryptococcal Meningitis in Ugandan Patients with AIDS". Clinical Infectious Diseases. 26 (6): 1362–1366. doi:10.1086/516372. ISSN 1058-4838. PMID 9636863.
  24. ↑ Jacob, Shevin T.; Moore, Christopher C.; Banura, Patrick; Pinkerton, Relana; Meya, David; Opendi, Pius; Reynolds, Steven J.; Kenya-Mugisha, Nathan; Mayanja-Kizza, Harriet; Scheld, W. Michael; Group¶, for the Promoting Resource-limited Interventions for Sepsis Management in Uganda (PRISM-U) Study (2009-11-11). "Severe Sepsis in Two Ugandan Hospitals: a Prospective Observational Study of Management and Outcomes in a Predominantly HIV-1 Infected Population". PLOS ONE. 4 (11): e7782. Bibcode:2009PLoSO...4.7782J. doi:10.1371/journal.pone.0007782. ISSN 1932-6203. PMC 2771355. PMID 19907656.
  25. ↑ Simmons, Jason D; Stein, Catherine M; Seshadri, Chetan; Campo, Monica; Alter, Galit; Fortune, Sarah; Schurr, Erwin; Wallis, Robert S; Churchyard, Gavin; Mayanja-Kizza, Harriet; Boom, W Henry (2018-09-01). "Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection". Nature Reviews Immunology. 18 (9): 575–589. doi:10.1038/s41577-018-0025-3. ISSN 1474-1741. PMC 6278832. PMID 29895826.
  26. ↑ Lu, L. L.; Smith, M. T.; Yu, K. K. Q.; Luedemann, C.; Suscovich, T. J.; Grace, P. S.; Cain, A.; Yu, W. H.; McKitrick, T. R.; Lauffenburger, D.; Cummings, R. D. (2019). "IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure". Nature Medicine. 25 (6): 977–987. doi:10.1038/s41591-019-0441-3. ISSN 1078-8956. PMC 6559862. PMID 31110348.
  27. ↑ Stein, Catherine M.; Zalwango, Sarah; Malone, LaShaunda L.; Won, Sungho; Mayanja-Kizza, Harriet; Mugerwa, Roy D.; Leontiev, Dmitry V.; Thompson, Cheryl L.; Cartier, Kevin C.; Elston, Robert C.; Iyengar, Sudha K. (2008-12-31). "Genome Scan of M. tuberculosis Infection and Disease in Ugandans". PLOS ONE. 3 (12): e4094. Bibcode:2008PLoSO...3.4094S. doi:10.1371/journal.pone.0004094. ISSN 1932-6203. PMC 2605555. PMID 19116662.
  28. ↑ Nakanjako, Damalie; Kamya, Moses; Daniel, Kyabayinze; Mayanja-Kizza, Harriet; Freers, Jurgen; Whalen, Christopher; Katabira, Elly (2007-09-01). "Acceptance of Routine Testing for HIV among Adult Patients at the Medical Emergency Unit at a National Referral Hospital in Kampala, Uganda". AIDS and Behavior. 11 (5): 753–758. doi:10.1007/s10461-006-9180-9. ISSN 1573-3254. PMID 17096199. S2CID 30398339.
  29. ↑ Chegou, Novel N.; Sutherland, Jayne S.; Malherbe, Stephanus; Crampin, Amelia C.; Corstjens, Paul L. A. M.; Geluk, Annemieke; Mayanja-Kizza, Harriet; Loxton, Andre G.; Spuy, Gian van der; Stanley, Kim; Kotzé, Leigh A. (2016-09-01). "Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB". Thorax. 71 (9): 785–794. doi:10.1136/thoraxjnl-2015-207999. ISSN 0040-6376. PMID 27146200. S2CID 5486603.
  30. ↑ Jacob, Shevin T.; Banura, Patrick; Baeten, Jared M.; Moore, Christopher C.; Meya, David; Nakiyingi, Lydia; Burke, Rebecca; Horton, Cheryl Lynn; Iga, Boaz; Wald, Anna; Reynolds, Steven J. (2012). "The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: A prospective intervention study*". Critical Care Medicine. 40 (7): 2050–2058. doi:10.1097/CCM.0b013e31824e65d7. ISSN 0090-3493. PMC 3378757. PMID 22564958.
  31. ↑ Nakanjako, Damalie; Ssewanyana, Isaac; Mayanja-Kizza, Harriet; Kiragga, Agnes; Colebunders, Robert; Manabe, Yukari C.; Nabatanzi, Rose; Kamya, Moses R.; Cao, Huyen (2011-02-08). "High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort". BMC Infectious Diseases. 11 (1): 43. doi:10.1186/1471-2334-11-43. ISSN 1471-2334. PMC 3065409. PMID 21299909.
  32. ↑ Sullivan, Richard T.; Kim, Charles C.; Fontana, Mary F.; Feeney, Margaret E.; Jagannathan, Prasanna; Boyle, Michelle J.; Drakeley, Chris J.; Ssewanyana, Isaac; Nankya, Felistas; Mayanja-Kizza, Harriet; Dorsey, Grant (2015-05-19). "FCRL5 Delineates Functionally Impaired Memory B Cells Associated with Plasmodium falciparum Exposure". PLOS Pathogens. 11 (5): e1004894. doi:10.1371/journal.ppat.1004894. ISSN 1553-7374. PMC 4438005. PMID 25993340.
  33. ↑ Leidl, L.; Mayanja-Kizza, H.; Sotgiu, G.; Baseke, J.; Ernst, M.; Hirsch, C.; Goletti, D.; Toossi, Z.; Lange, C. (2010-03-01). "Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection". European Respiratory Journal. 35 (3): 619–626. doi:10.1183/09031936.00045509. ISSN 0903-1936. PMID 19608590. S2CID 8348467.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.